CLINICAL TRIALS PROFILE FOR MAPRACORAT

Clinical Trials for Mapracorat

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00905450 ↗	Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery	Completed	Bausch & Lomb Incorporated	Phase 2	This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
NCT01228513 ↗	Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)	Completed	Bayer	Phase 2	The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
NCT01230125 ↗	Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery	Completed	Bausch & Lomb Incorporated	Phase 3	The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
NCT01289431 ↗	Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis	Completed	Bausch & Lomb Incorporated	Phase 2	The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.
NCT01298752 ↗	Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery	Terminated	Bausch & Lomb Incorporated	Phase 3	The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
NCT01359787 ↗	Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)	Completed	Bayer	Phase 2	The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to ointment base (vehicle) in subjects with Atopic Dermatitis (AD).
NCT01407510 ↗	HPA Axis Study in Japanese Adults	Completed	Bayer	Phase 2	A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in Japanese adults with atopic dermatitis.

Clinical Trial Conditions for Mapracorat

Condition Name

Condition Name
Intervention	Trials
Cataract	5
Inflammation	4
Atopic Dermatitis	4
Eczema	3

Condition MeSH

Condition MeSH
Intervention	Trials
Inflammation	5
Cataract	5
Eczema	4
Dermatitis, Atopic	4

Clinical Trial Locations for Mapracorat

Trials by Country

Trials by Country
Location	Trials
United States	17
Germany	2
Japan	2
South Africa	1

Trials by US State

Trials by US State
Location	Trials
New York	8
Massachusetts	1
Illinois	1
Idaho	1
Hawaii	1

Clinical Trial Progress for Mapracorat

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	6
Phase 1	2

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	11
Terminated	1

Clinical Trial Sponsors for Mapracorat

Sponsor Name

Sponsor Name
Sponsor	Trials
Bausch & Lomb Incorporated	7
Bayer	5

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	12